Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: A pilot study

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 1, 2012, Pages 57-71

  Piccardo, Arnoldo ^a   Lopci, Egesta ^b   Conte, Massimo ^c   Garaventa, Alberto ^c   Foppiani, Luca ^a   Altrinetti, Vania ^a   Nanni, Cristina ^b   Bianchi, Pietro ^a   Cistaro, Angela ^d   Sorrentino, Stefania ^c   Cabria, Manlio ^a   Pession, Andrea ^b   Puntoni, Matteo ^a   Villavecchia, Giampiero ^a   Fanti, Stefano ^b  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d IRMET   (Italy)

Author keywords

123I MIBG scintigraphy; 18F dopa; Neuroblastoma; PET CT

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; DOPA; FLUORINE 18; IASODOPA; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE; 6 FLUORODOPA F 18; DIAGNOSTIC AGENT; DRUG DERIVATIVE;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER RELAPSE; CANCER STAGING; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; NEUROBLASTOMA; PILOT STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; COMPARATIVE STUDY; INFANT; METHODOLOGY; PATHOLOGY; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ADULT; CHILD; CHILD, PRESCHOOL; DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; INFANT; MALE; NEOPLASM STAGING; NEUROBLASTOMA; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 84858776675     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1938-2     Document Type: Article

References (40)

1. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid: Children's Cancer Group. N Engl J Med 1999;341:1165-73. (Pubitemid 29480654)
2. Braduer GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77. (Pubitemid 23228250)
3. Vaidyanathan G. Meta-iodobenzylguanidine and analogues: chemistry and biology. Q J Nucl Med Mol Imaging 2008;52:351-68.
4. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27:298-303.
5. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2- [fluorine-18]-fluoro-2- deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996;199:743-50.
6. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001;19:3397-405. (Pubitemid 32642193)
7. Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004;45:1172-88. (Pubitemid 47611663)
8. Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009;27:5343-9.
9. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009;50:1237-43.
10. Minn H, Kauhanen S, Seppänen M, Nuutila P. 18F-FDOPA: a multiple-target molecule. J Nucl Med 2009;50(12):1915-8.
11. Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab 2010;95(6):2800-10.
12. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluorodeoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009;94(12):4757-67.
13. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001;220:373-80. (Pubitemid 32667172)
14. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64-71. (Pubitemid 32120808)
15. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, et al. Pheochromocytomas: detection with 18F-DOPA whole body PET-initial results. Radiology 2002;222:507-12. (Pubitemid 34106126)
16. Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123) I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 2009;94(10):3922-30.
17. Luxen A, Perlmutter M, Bida GT, Van Moffaert G, Cook JS, Satyamurthy N, et al. Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET. Int J Rad Appl Instrum A 1990;41(3):275-81. (Pubitemid 20111171)
18. Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47:865-74. (Pubitemid 44656106)
19. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998;39:679-88. (Pubitemid 28175849)
20. Osmanagaoglu K, Lippens M, Benoit Y, Obrie E, Schelstraete K, Simons M. A comparison of iodine-123 meta-iodobenzylguanidine scintigraphy and single bone marrow aspiration biopsy in the diagnosis and follow-up of 26 children with neuroblastoma. Eur J Nucl Med 1993;20:1154-60. (Pubitemid 24035318)
21. Moyes JSE, Babich JW, Carter R, Meller ST, Agrawal M, McElwain TJ. Quantitative study of radioiodinated metaiodobenzylguanidine uptake in children with neuroblastoma: correlation with tumor histopathology. J Nucl Med 1989;30(4):474-80. (Pubitemid 19096592)
22. Lebtahi Hadj-Djilani N, Lebtahi NE, Bischof Delaloye A, Laurini R, Beck D. Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur J Nucl Med 1995;22:322-9.
23. Geatti O, Shapiro B, Sisson JC, Hutchinson RJ, Mallette S, Eyre P, et al. Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med 1985;26:736-42. (Pubitemid 16005495)
24. Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989;30:481-9. (Pubitemid 19096593)
25. Biasotti S, Garaventa A, Villavecchia GP, Cabria M, Nantron M, De Bernardi B. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol 2000;35:153-5.
26. Giammarile F, Lumbroso J, Ricard M, Aubert B, Hartmann O, Schlumberger M, et al. Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high dose on tumour site detection. Eur J Nucl Med 1995;22:1180-3.
27. Bonnin F, Lumbroso J, Tenenbaum F, Hartmann O, Parmentier C. Refining interpretation of MIBG scans in children. J Nucl Med 1994;35:803-10. (Pubitemid 24151215)
28. Melzer HI, Coppenrath E, Schmid I, Albert MH, von Schweinitz D, Tudball C, et al. (123)I-MIBG scintigraphy/SPECT versus (18) F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging 2011;38:1648-58.
29. Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer 2009;45:2835-42.
30. Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JC, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial. Pediatr Blood Cancer 2009;52:784-90.
31. Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR. 123I-meta- iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a metaanalysis. J Clin Endocrinol Metab 2010;95:2596-606.
32. Feine U, Müller-Schauenburg W, Treuner J, Klingebiel T. Metaiodobenzylguanidine (MIBG) labeled with 123I/131I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology held in Rome, September 1986. Med Pediatr Oncol 1987;15(4):181-7. (Pubitemid 18025974)
33. Hoefnagel CA, VoÛte PA, de Kraker J, Marcuse HR. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 1987;28:308-14. (Pubitemid 17049463)
34. Okuyama C, Ushijima Y, Kubota T, Nakamura T, Kikkawa M, Nishimura T. Utility of follow-up studies using meta-[123 I] iodobenzylguanidine scintigraphy for detecting recurrent neuroblastoma. Nucl Med Commun 2002;23:663-72. (Pubitemid 34748006)
35. McDowell H, Losty P, Barnes N, Kokai G. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer 2009;52:552.
36. Kushner BH, Kramer K, Modak S, Cheung NK. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol 2009;27:1041-6.
37. Colavolpe C, Guedj E, Cammilleri S, Taieb D, Mundler O, Coze C. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer 2008;51:828-31.
38. Frappaz D, Bonneu A, Chauvot P, Edeline V, Giammarile F, Siles S, et al. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group. Med Pediatr Oncol 2000;34:237-41. (Pubitemid 30176598)
39. Schwarz KB, Driver I, Lewis IJ, Taylor RE. Positive MIBG scanning at the time of relapse in neuroblastoma which was MIBG negative at diagnosis. Br J Radiol 1997;70:90-2. (Pubitemid 27077564)
40. Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, et al. Criteria for evaluation of disease extent by (123)I- metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010;102:1319-22.